Document:

​

Exhibit 10.29
BrightMark Consulting, LLC
42 Harbor Avenue 
Westport, CT 06880
January 6, 2021
Marpai Health, Inc.
14 Todd Drive
East Hampton, NY 11937
Dear Mr. Gonzalez:
This letter agreement together with the exhibit attached hereto (collectively, the “Agreement”) shall constitute the consulting/services agreement by and between BrightMark, LLC (“Consultant”) and Marpai Health, Inc. (“Client”).
1.Term of Agreement: This Agreement shall be effective as of the date set forth above, and shall continue in full force and effect for such time as set forth in the Workscope attached hereto as Schedule 1 (the “Workscope”), unless extended by mutual agreement or terminated in accordance with Section 3 hereof (the “Term”).
2.Services:
(a)Scope of Services
Consultant will provide the Services set forth in the Workscope (the “Services”). In the event Client requests a change in the scope of Services, which change is accepted by Consultant, Consultant shall provide Client with a new Workscope reflecting such changes as are agreed upon by Client and Consultant. Per the following subparagraph (b), all changes to the Workscope shall be reflected in a new Workscope, which will then be attached hereto as Schedule 1, or as supplements to the Workscope, as the case may be.
(b)Workscope Content
All changes to the Workscope per (a) above, if any, will include, to the extent appropriate, (a) a description of the Services; (b) the timetable for the performance of the Services; (c) the additional amounts payable to Consultant for such Services; (d) the basis on which such amounts are payable; and (e) the schedule on which such amountswill be invoiced to Client.
3.Early Termination: Consultant and Client each have the right to terminate this agreement at any time and for any reason upon 30 days advance written notice to the other party, said notice to be in accordance with 1114 hereof. Client shall remain responsible for payment of all Fees and Expenses due or incurred prior to the Termination Date, defined as 30 days after Effective Notice as defined in ¶14 (“Termination Date”). Except as otherwise provided herein, the party terminating this Agreement shall not be liable to the other party for any additional costs, losses, damages, or liabilities, including, without limitation, loss of anticipated profits or reimbursement for Services unperformed as a result of the termination. Notwithstanding 
​
​

​

​

anything herein, Client shall pay Consultant in accordance with 114 below through the Termination Date.
4.Client’s Obligations:
(a)Compensation.  Client shall pay the total of all Professional Fees (as set forth in the Workscope) in the following manner: 50% upfront to initiate project, 30% by February 8, 2021 and 20% by March 30, 2021 upon receipt of final deliverables.
(b)Expenses.  Professional Fees are inclusive of standard out of pocket costs (e.g. shipping, phone, photocopying, printing, etc.) which are covered by G&A set forth in the Workscope. Any travel or any additional expenses approved by Client to complete the Workscope, or creative materials requested by client that are out of Workscope, incurred by Consultant during the Term and prior to the Termination Date will be reimbursed to Consultant by Client within fifteen (15) days after receipt of Consultant’s invoice for expenses. Any such expenses will be invoiced monthly.
(c)Late Fees.  Client shall pay a late fee of five percent (5%) per month on all payments or portions thereof that are not received by the date payment is due, until said payment is received in full.
5.Consultant’s Representations and Warranties: Consultant represents and warrants that: (a) it is free to enter into this Agreement and to perform its obligations hereunder without objection from or claim of anyone; (b) the Services and any resulting work product may be conveyed to Client free and clear of claim of ownership by others; (c) the Services and any resulting work product created or modified by the Consultant will not violate or infringe upon the rights of any third party, including (i) proprietary information and non-disclosure rights, (ii) copyrights, patent or other intellectual property rights, and (iii) contractual rights; (d) the Services shall not violate any applicable law, rule, or regulation; and (e) the Services will be rendered in a professional manner. Except for the foregoing warranties, Consultant makes no other warranties, whether express, implied or statutory, regarding or relating to any materials or the Services provided to Client under this Agreement. Consultant specifically disclaims any and all implied warranties of merchantability or fitness for a particular purpose.
6.Indemnification:  Consultant and Client shall indemnify and hold the other harmless against any and all costs, losses or expenses (including reasonable attorneys’ fees) that the other may incur, or be subjected to, in respect of the indemnifying party’s breach of any of its obligations hereunder. Each party shall defend the other at the other’s request against any such liability, claim or demand. Each party shall notify the other promptly of written claims or demands against such party of which the other party is responsible hereunder. Each party shall cooperate fully with the other, and the indemnifying party shall control such defense and the right to litigate, settle, appeal (provided it pays the cost of any required appeal bond), compromise or otherwise deals with any such claim or resulting judgment; provided that such settlement, compromise or other resolution of such claim does not result in any liability to the indemnified party. These provisions will survive the termination of this Agreement. In no event shall either party be liable to the other party for any of its incidental, indirect, special or 
​

2

​

consequential damages, regardless of the nature of the claim, even if such party knew or should have known of the possibility of such damages or claims.
7.Ownership:
(a)By Client.  Upon payment of all of the Fees and Compensation set forth in the Workscope, all of Consultant’s work products prepared, produced or developed for Client under this Agreement, including all concepts, designs, files, reports, programs, manuals, listings, data bases and any other materials (whether complete or incomplete, whether acceptable to Client or not, and regardless of the form they take) shall become the property of Client, exclusively. At such time, Consultant shall unconditionally assign and transfer to Client all right, title, interest and claim that it has or may in the future have to those work products.
(b)By Consultant.  Notwithstanding the foregoing, any pre-existing materials (including software source code, object code and documentation related thereto), and other creative and technical content, developed before the applicable Workscope, and all enhancements, modifications and updates thereto, provided by Consultant or its suppliers (collectively, the “Pre-Existing Consultant Materials”) shall be the sole and exclusive property of Consultant or such supplier(s), as appropriate; and all rights related thereto, including, without limitation, copyrights, trademarks, trade secrets, patents, and other intellectual property or proprietary rights, are hereby exclusively reserved by Consultant or its applicable owner. It is expressly understood that no title to or ownership of the Pre-Existing Consultant Materials is transferred to Customer under this Agreement unless explicitly set forth in the Workscope.
8.Non-Exclusivity:  This work relationship by and between Consultant and Client is non-exclusive and, except as otherwise set forth herein, nothing in this Agreement shall restrict either party from providing, or engaging other persons to provide, services similar to those contemplated hereunder to persons and entities that are not party to this Agreement, whether at time within or without the time period of this Agreement.
9.Confidentiality:
(a)General.  From time to time, either party may disclose or make available to the other party, either directly or through one or more third party contractors and suppliers, whether orally or in physical form, confidential or proprietary information concerning the  disclosing party and/or its products, services, methods, techniques, processes, strategies and business plan as well as the technology and software associated therewith (together, “Confidential Information”) in connection with the transactions contemplated hereunder. Each party agrees that during the term of this Agreement and thereafter: (a) it will use Confidential Information belonging to the other party solely for the purpose(s) of this Agreement; (b) it will not disclose Confidential Information belonging to the other party to any third party (other than the receiving party’s employees and/or professional advisors on a need-to-know basis who are bound by obligations of nondisclosure and limited use at least as stringent as those contained herein); (c) it will use the same standard of care it uses to protect its own Confidential Information to protect the Confidential Information belonging to the other party provided that in no event will such standard of care be less than a reasonable degree of care; (d) it will not copy, reproduce, distribute, decompile or reverse engineer any of the Confidential Information or in any way 
​

3

​

attempt to derive source or object code from the Confidential Information; and (e) it will, upon request, promptly return and deliver to the disclosing party all Confidential Information.
(b)Exclusions.  For purposes hereof, “Confidential Information” will not include information which the receiving party can establish: (a) is independently developed by the receiving party without use of or reference to any Confidential Information belonging to the other party as evidenced by appropriate independent written documentation; (b) is acquired by the receiving party from a third party having the legal right to furnish same to the receiving party; (c) is at the time in question (whether at disclosure or thereafter) generally known by or available to the public (through no fault of the receiving party); or (d) is required to be disclosed pursuant to a final order of a court of competent jurisdiction.
(c)Court Orders.  In the event either party is requested or ordered by a court of competent jurisdiction to disclose Confidential Information belonging to the other party, such party will give the other party immediate notice of such request or order and, at the other party’s request and expense, resist such request or order to the fullest extent permitted by law.
10.Subcontractors:  It is hereby agreed that Consultant shall have the authority to subcontract any or all of its duties under this Agreement and may retain third parties to furnish consulting services to it, in connection with its performance of this Agreement.
11.Entire Agreement.  This letter together with its Schedules and Exhibits describes the entire agreement between Consultant and Client with respect to its subject matter. Any prior arrangements, agreements, contracts, representations, warranties, purchase orders, bids, proposals, offers, or other communications, written or oral, are superseded and of no force or effect. This letter agreement may not be changed orally; it may be changed only by means of writing, signed by both Consultant and an authorized Client representative.
12.Independent Contractor:  The parties to this Agreement are independent contractors and nothing contained herein may be construed to place the parties in the relationship of employer and employee, partners, principal and agent, or joint ventures. Neither party has the power to bind or obligate the other party, nor shall either party hold itself out as having such authority.
13.Force Majeure.  Neither party shall be liable for any delays or failures in performance due to circumstances beyond its control. If the performance of this Agreement, or any obligation hereunder, is prevented, restricted or interfered with by reason of (i) acts of God; (ii) war, revolution, civil commotion, acts of public enemies, blockage or embargo; (iii) acts of the government in its sovereign capacity; or (iv) any other circumstances beyond the reasonable control and without the fault or negligence of the party affected, the party affected, upon giving prompt notice to the other party, shall be excused from such performance on a day-to-day basis to the extent of such prevention, restriction, or interference (and the other party shall likewise be excused from performance of its obligations on a day-to-day basis to the extent such party’s obligations are related to the performance so prevented, restricted or interfered with); provided, however, that all payment obligations arising prior to such cause shall remain in full force; and further provided, however, that the party so affected shall use its best efforts to avoid or remove 
​

4

​

such causes of non-performance and both parties shall proceed whenever such causes are removed or cease.
14.Notices.  Any notice or other communications given pursuant to this Agreement shall be in writing and shall be effective (“Effective Notice”) either when delivered personally to the party for whom intended, or five (5) days following deposit of the same into the United States mail (certified mail, return receipt requested), or two (2) days following the deposit of the same with an overnight or other express delivery service, addressed to such party at the address set forth on the initial page of this Agreement. Copies of all written notices provided to Consultant shall also be provided to Scott R. Lucas, Esq., Lucas & Varga LLC, 2425 Post Road, Suite 200, Southport, CT 06890; as for Client, to: Edmundo Gonzalez, CEO, Marpai Health, Inc. 14 Todd Drive, East Hampton, NY 11937 Either party may designate a different address by notice to the other given in accordance herewith.
15.Section Headings.  The headings of each Section are for reference only and shall not be construed as part of this Agreement.
16.Invalidity of any Provision.  If any term or provision of this Agreement shall be found by shall not effect the other terms or provisions hereof or the whole of this Agreement, but such term or provision shall be deemed modified to the extent necessary in the court's opinion to render such term or provision enforceable, and the rights and obligations of the parties shall be construed and enforced accordingly, preserving to the fullest permissible extent the intent and agreements of the parties herein set forth.
17.No Waiver.  The failure of either party to take action as a result of a breach of this Agreement by the other party shall constitute neither a waiver of the particular breach involved nor a waiver of either party's right to enforce any or all provisions of this Agreement through any remedy granted by law or this Agreement.
18.Governing Law. This Agreement will be governed by, construed and enforced in accordance with the laws of the State of Connecticut, without giving effect to conflict of law principles. Each party hereto consents to the sole and exclusive subject matter and in personam jurisdiction and venue at the Connecticut state courts and/or the United States District Court of Connecticut.
	​

	

	

	​
	Very truly yours,

	​
	​

	​
	BrightMark Consulting

	​
	​

	​
	By:
	/s/ Jane Cavalier

	​
	​
	Jane Cavalier

	​
	​
	Founder/CEO

​
​

5

​

​
	The foregoing is accepted and agreed to
	​
	​

	as of the Effective Date set forth herein
	​
	​

​
​
	​

	​

	

	

	Marpai Health, Inc.
	
	​
	​
	​

	By:
	/s/ Edmundo Gonzalez
	​

	​
	Edmundo Gonzalez
	
	​
	CEO
	
	​
	​
	​

	​
	​
	​

​

6​

Exhibit 10.30
MARPAI, INC.
​
Mr. Lutz Finger
Via electronic mail
​
Dear Lutz:
Marpai, Inc. (the “Company”) is pleased to offer you employment on the following terms:
1.Position; Start Date.  Your initial title will be President – Product and Development, and you will initially report to the Company’s Chief Executive Officer.  This is a full-time position.  While you render services to the Company, you will not engage in any other employment, consulting or other business activity (whether full-time or part-time) that would create a conflict of interest with the Company or interfere with the performance of your duties to the Company. Subject to any pre-employment requirements, your employment with the Company will begin on Feb 28, 2022, or such other day as you and the Company may agree (the “Start Date”).
​
2.Mission.  As the Company’s President – Product and Development, your initial mission will be:

		●	To lead product strategy in a manner that will differentiate the Company over the coming 3-5 years.

​
		●	To create a formal product management function within the Company with the goal of giving clarity and guidance on what is developed (including how and when) to the technology departments within the Company.

​
		●	To be the internal client of the Company’s engineering and development efforts in a way that aligns these efforts to the market.

​
3.Scope of Authority.  As the Company’s President – Product and Development, your initial scope of authority will comprise the following:
		●	You shall be an officer of the Company, and you shall be included as such in filings related to our management with the Securities and Exchange Commission.

		●	All product management functions as well as engineering and development (currently housed in Marpai Labs and in the technology team in Tampa) shall report to you.

		●	You shall also be responsible for building a formal product management function for the Company.

​
4.Base Salary.  The Company will pay you a base salary at the initial rate of Three Hundred Twenty-Five Thousand Dollars ($325,000) per year, payable in accordance with the Company’s standard payroll schedule.  This salary will be subject to adjustment pursuant to the Company’s employee compensation policies in effect from time to time.
5.Annual Bonus Opportunity.  You will be eligible for an annual bonus with a target of 50% of your base salary (the “Annual Bonus”).  The actual Annual Bonus could be larger or smaller than this amount, based on your achievement of performance metrics, which shall be determined by the Company at
​
​

​

Page 2
​

its sole and absolute discretion at the beginning of each year.  The CEO will determine the attainment of performance targets and the Annual Bonus amount in the CEO’s reasonable discretion.
6.Sign-On Bonus.
		(a)	The Company will pay you a one-time sign-on bonus, in cash or in freely tradeable shares of the Company’s common stock, in an amount equal to Two Hundred Fifty Thousand Dollars ($250,000).

		(b)	If paid in cash, the Company will pay the sign-on bonus within fifteen (15) days following your Start Date. Should your employment with the Company end, other than as a result of the Company terminating you without Cause, your terminating your employment for Good Reason, or termination due to your death or Disability (each term as defined below), within your first twelve (12) months of employment, you agree to repay the cash Sign-On Bonus in full.

		(c)	If paid in stock, the Company will issue the shares promptly following the 12-month anniversary of the Start Date, and the number of shares will equal $250,000 divided by the fair market value per share, as determined by the Company’s Board of Directors.  The Board of Directors will determine the fair market value per share based on the volume weighted average closing price per share of the Company’s common stock on the NASDAQ Market on the ten (10) consecutive trading days immediately preceding the date of grant.

7.Renewal Bonus.
		(a)	Should the Company renew your employment and this letter agreement upon expiration of the initial two-year term, the Company will pay you a one-time renewal bonus, in cash or in freely tradeable shares of the Company’s common stock, in an amount equal to Two Hundred Fifty Thousand Dollars ($250,000).

		(b)	If paid in cash, the Company will pay the renewal bonus within fifteen (15) days following the second anniversary of the Start Date. Should your employment with the Company end, other than as a result of the Company terminating you without Cause, your terminating your employment for Good Reason, or termination due to your death or Disability (each term as defined below), within the second and third anniversaries of the Start Date, you agree to repay the cash Renewal Bonus in full.

		(c)	If paid in stock, the Company will issue restricted shares promptly following the two-year anniversary of the Start Date, and the number of shares will equal $250,000 divided by the fair market value per share on the 12-month anniversary of the Start Date, as determined by the Company’s Board of Directors.  The Board of Directors will determine the fair market value per share based on the volume weighted average closing price per share of the Company’s common stock on the NASDAQ Market on the ten (10) consecutive trading days immediately preceding the date of grant.  The restrictions on the shares will be lifted twelve (12) months following the date of grant provided you remain an employee in good standing of the Company on such date.

​
8.Taxes.  All forms of compensation referred to in this letter agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law.  You agree that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or its Board of Directors related to tax
​

​

Page 3
​

liabilities arising from your compensation.   The Company encourages you to consult a tax professional concerning all tax reporting requirements related to your compensation and benefits.
9.Employee Benefits.  As a regular full-time employee of the Company, you will be eligible to participate in a number of Company-sponsored benefits offered to similarly-situated Company employees, in accordance with the terms of such employee benefit policies and plans.  Among other things, these benefits include medical and dental insurance, a 401(k) retirement plan, as well as disability insurance and life insurance as provided to other employees.  In addition, you will be entitled to paid vacation in accordance with the Company’s vacation policy, as in effect from time to time.  The Company may modify its employee benefit plans at any time in its discretion.
	10.
	Equity Grants.

		(a)	Subject to the approval of the Company’s Board of Directors, you will receive a restricted stock grant (the “Initial Equity Grant”) of that number of shares of the Company’s common stock equal to Two Million Dollars ($2,000,000) divided by the fair market value per share on the date of the grant, as determined by the Company’s Board of Directors.  The Initial Equity Grant will vest in equal quarterly installments during the 12-month period following the Start Date.

​
		(b)	Subject to the approval of the Company’s Board of Directors, following the one-year anniversary of the Start Date, you will receive a restricted stock grant (the “Additional Equity Grant – Year 2”) of that number of shares of the Company’s common stock equal to Two Million Dollars ($2,000,000) divided by the fair market value per share on the date of the grant, as determined by the Company’s Board of Directors.  The Board of Directors will determine the fair market value per share based on the volume weighted average closing price per share of the Company’s common stock on the NASDAQ Market on the ten (10) consecutive trading days immediately preceding the date of grant of the Additional Equity Grant – Year 2.  The Additional Equity Grant – Year 2 will vest in equal quarterly installments during the 12-month period following the one-year anniversary of the Start Date.

​
		(c)	With respect to the Initial Equity Grant and the Additional Equity Grant -Year 2, the Board of Directors will determine the fair market value per share based on the volume weighted average closing price per share of the Company’s common stock on the NASDAQ Market on the ten (10) consecutive trading days immediately preceding the date of grant (the “Grant Date Price”).

​
		(d)	All equity grants are subject to the terms of the Marpai, Inc. Global Stock Incentive Plan (2021) or such other equity incentive plan as may be in effect on the date of the applicable grant.  The specific terms and conditions of each equity grant will be set forth in the applicable award agreement evidencing such equity grant.

​
		(e)	In the case that the market price per share on any of the vesting dates is less than the Grant Date Price, the Company shall issue you a payment for the difference in cash or freely tradeable shares so that the vested amount is equal to the product of the vesting shares for that quarter multiplied by the Grant Date Price.

​
​

​

Page 4
​

11.Blackout Periods.  You acknowledge that you will be subject to restrictions on trading or effectuating any other transactions in the Company’s securities during regular blackout periods and during any special blackout periods designated by the Company.  You further acknowledge that even during an open trading window, you may not trade in the Company’s securities if you are in possession of material nonpublic information concerning the Company or its securities.
12.Proprietary Information and Inventions Agreement.  As a senior executive of the Company, you will have access to the Company’s proprietary and confidential information.  In consideration for and as a requirement of your employment, you will be required to sign the Company’s standard Proprietary Information and Inventions Agreement, a copy of which is attached hereto as Exhibit A.
13.No Conflict. By signing this letter agreement, you confirm to the Company that you have no contractual commitments or other legal obligations that would prohibit you from performing your duties for the Company.
14.Term.  Unless earlier terminated in accordance with Section 14, your employment under this letter agreement will begin on the Start Date and shall continue for a term of two (2) years.  Following expiration of the initial two-year term of employment, the term will automatically renew for successive one-year periods unless either you or the Company delivers a notice of non-renewal at least one month prior to the expiration of the then-current period.
15.Termination.
1.(a)Your employment with the Company may terminate      due to your death, your Disability (as defined below), your voluntary termination, termination by the Company for Cause (as defined below), or termination by the Company without Cause.
		(b)
	“Disability” means your physical or mental injury, illness or incapacity as a result of which you are unable to perform the essential functions of your position (after an interactive process that accounts for reasonable accommodation) and such inability is expected to last permanently or has existed for a period of sixty (60) days within any 12-month period.

​
		(c)
	“Cause” means:

​
(i) Your willful and continued failure to perform your duties and responsibilities which remains uncured for a period of thirty (30) days following written notice of such failure from the Company to you;
​
(ii) Your proven willful dishonesty, fraud or misconduct with respect to the business or affairs of the Company that materially and adversely affects the Company provided you have a reasonable opportunity to be heard and defend your actions;
​
(iii) the indictment of, or the bringing of formal charges against, you on charges involving, or a conviction of, a felony or any crime involving an act of dishonesty, moral turpitude, deceit or fraud against the Company or theft, misappropriation or embezzlement of funds of the Company; or
​
​

​

Page 5
​

(iv) Your having committed acts of omission constituting an intentional, knowing, or grossly negligent breach of your duty of loyalty or fiduciary duty to the Company or any material act of dishonesty or fraud with respect to the Company which is not cured or substantially cured to the satisfaction of the Board in a reasonable time, which time shall be at least thirty (30) days from receipt of written notice from the Company of such material breach;
​
(v) your material breach of this letter agreement that is not cured (if curable) within thirty (30) days following written notice from the Company of such breach; or
​
(vi) any material violation of the Company’s policies including, but not limited to, the Company’s policies against harassment, discrimination or retaliation that is not cured (if curable) within thirty (30) days following written notice from the Company of such violation.
​
(d)“Good Reason” means:
​
the occurrence without your consent: (i) of a material reduction in the your compensation terms, taken as a whole, which is not applied on a broad basis to similar situated employees not to exceed 10%; (ii) a reduction in your title or a material reduction in the scope of authorities and/or responsibilities; (iii) a non-consensual change of more than thirty (30) miles in the geographic location at which you currently provide services to the Company; or (iv) any action or inaction that constitutes a material breach of any provision by the Company of this Agreement or any other agreement between you and the Company provided further, that in each case, you notified the Company (or its successor, as applicable), within thirty (30) days after the occurrence of any such failure, and the Company (or its successor, as applicable) failed to cure such event within thirty (30) days after the receipt of such notice and you terminate employment within thirty (30) days following the expiration of the cure period.
​
16.Severance Benefits.  If: (i) the Company terminates your employment without Cause, (ii) the Company declines to renew this letter agreement and your employment upon expiration of the initial two-year term or any successive one-year term,  or (iii) you terminate your employment for Good Reason, then (x) the Company will pay your base salary through the date that is six (6) months following the termination date (the "Severance Period") payable in regular installments as special severance payments, but in no event less frequently than monthly, (y) you shall be entitled to receive any earned, but unpaid, Annual Bonus, pro-rated through the employment termination date, and (z) the Company will issue to you the shares from the Initial Equity Grant and any shares from the Additional Equity Grant – Year 2 that would have vested as of the employment termination date (collectively, the “Severance Benefits”).   Notwithstanding anything herein to the contrary, you shall not be entitled to receive any Severance Benefits unless you have executed and delivered to the Company a general release in favor of the Company in a form attached hereto as Exhibit B (the "General Release"), and such General Release is in full force and effect and has not been revoked.
17.Change in Control.  In the event that the Company: (a) consummates a Merger/Sale (as defined in the Plan), and (b) during the 3 months preceding and 18 months following the consummation of the Merger/Sale your employment is terminated by the Company not for Cause (as defined in the Plan) or by you for Good Reason (as defined below),  then in such case, 100% of any equity grants issued under Section 10 shall accelerate and become fully vested and exercisable as of such termination date, provided that upon
​

​

Page 6
​

such termination, you execute and do not revoke (during any applicable revocation period) the General Release.
18.Indemnification.  The Company shall indemnify you, to the maximum extent permitted by applicable law, against all costs, charges and expenses incurred or sustained by you in connection with any action, suit or proceeding to which you may be made a party by reason of you being an officer or employee of the Company or of any subsidiary or affiliate of the Company.  This indemnification shall be pursuant to a mutually agreeable Indemnification Agreement, which shall be no less protective of you than any indemnification agreement with the Company’s current officers and directors.  The Company shall maintain in full force and effect directors’ and officers’ liability insurance in reasonable amounts from established and reputable insurers and provide you coverage under such insurance policies.
19.Interpretation, Amendment and Enforcement.  This letter agreement and Exhibits A and B constitute the complete agreement between you and the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company.  This letter agreement may not be amended or modified, except by an express written agreement signed by both you and a duly authorized officer of the Company.  The terms of this letter agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this letter agreement or arising out of, related to, or in any way connected with, this letter agreement, your employment with the Company or any other relationship between you and the Company (the “Disputes”) will be governed by      California law, excluding laws relating to conflicts or choice of law.
20.Arbitration.  Except as otherwise prohibited by law, any controversy or claim arising out of this letter agreement and any and all claims relating to your employment with the Company will be settled by final and binding arbitration.  The arbitration shall be administered by Judicial Arbitration and Mediation Services (“JAMS”) pursuant to the pertinent JAMS Employment Arbitration Rules & Procedures as then in effect located at http://www.jamsadr.com.  The arbitration shall be conducted in a location selected by you in sole and complete discretion. Any award or finding will be confidential.  You and the Company agree to provide one another with reasonable access to documents and witnesses in connection with the resolution of the dispute.  You and the Company will share the costs of arbitration equally.  Each party will be responsible for its own attorneys’ fees, and the arbitrator may not award attorneys’ fees unless a statute or contract at issue specifically authorizes such an award.  This Section does not apply to claims for workers’ compensation benefits or unemployment insurance benefits.   This Section also does not apply to claims concerning the ownership, validity, infringement, misappropriation, disclosure, misuse or enforceability of any confidential information, patent right, copyright, mask work, trademark or any other trade secret or intellectual property held or sought by either you or the Company (whether or not arising under the Proprietary Information and Inventions Agreement between you and the Company).
* * * * *
This offer of employment is contingent upon verification of your authorization to work in the United States, background screening, and your execution of the Proprietary Information and Inventions Agreement.    We hope that you will accept our offer to join the Company.  You may indicate your agreement with these terms and accept this offer by signing and dating both this letter agreement and the enclosed Proprietary Information and Inventions Agreement and returning them to me.  This offer, if not accepted, will expire at the close of business on Jan 28th, 2022.
​

​

Page 7
​

If you have any questions, please call me at (646) 303-3483.
	​

	​

	​

	​
	Very truly yours,

	​
	​

	​
	​

	​
	MARPAI, INC.

	​
	​

	​
	​

	​
	By:
	/s/ Edmundo Gonzalez

	​
	​
	Edmundo Gonzalez, CEO

​
​
I have read and accept this employment offer:
​
​
	​

	​

	​
	​

	​
	​

	/s/ Lutz Finger
	​

	Signature of Lutz Finger
	​

​
Dated:  February 28, 2022
Attachment
Exhibit A: Proprietary Information and Inventions Agreement
Exhibit B: Release and Waiver of Claims

​

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]